bioAffinity Technologies vs MaxCyte
BIAF and MXCT side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BIAF and MXCT compare
MaxCyte is the larger company, worth 48 times as much as bioAffinity Technologies ($123M against $2.6M).
MaxCyte grew revenue faster over the last twelve months (−0.13% versus −18.5% for bioAffinity Technologies).
MaxCyte keeps more of each dollar of sales as profit, with a net margin of −81.4% compared with −279% at bioAffinity Technologies.
MaxCyte scores higher on the StockData Score (11 against 5 for bioAffinity Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BIAF | MXCT |
|---|---|---|
| Size and price | ||
| Market cap | $2.6M | $123M |
| Share price | $2.20 | $1.19 |
| Change, 1 year | −93.2% | −24.7% |
| Change, 5 years | – | −90.7% |
| Beta (5Y) | −1.10 | 1.54 |
| Employees | 57 | 91 |
| StockData Score | ||
| Total score | 5 | 11 (better) |
| Valuation score | 3 | 3 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.5× (better) | 3.6× |
| P/B | 0.7× (better) | 0.8× |
| FCF yield | −508% | −17.5% (better) |
| Fair value | $11.85 | $3.13 |
| Margin of safety | 81.4% (better) | 61.9% |
| Growth | ||
| Revenue growth (TTM) | −18.5% | −0.13% (better) |
| Revenue growth, 5Y average | – | 4.8% |
| Profitability | ||
| Gross margin | – | 81.0% |
| Operating margin | −246% | −98.0% (better) |
| Net margin | −279% | −81.4% (better) |
| FCF margin | −236% | −62.4% (better) |
| Return on equity | −240% | −16.9% (better) |
| Return on invested capital | −694% | −42.9% (better) |
| Financial health | ||
| Debt / equity | 0.05 (better) | 0.00 |
| Interest coverage | −270.9× | – |
| Current ratio | 1.51 | 7.83 (better) |
| Altman Z-score | −19.56 | 0.48 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 11.1% | 61.3% |
| Held by insiders | – | 8.0% |
| Insider net buying, 12 months | – | −$8.3K |
| Short interest, % of float | – | 1.7% |
Go deeper
- BIAF stock overview
- BIAF income statement
- BIAF valuation and score
- MXCT stock overview
- MXCT income statement
- MXCT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.